Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inhibikase Therapeutics, Inc. (Nasdaq: IKT) SEC filings page on Stock Titan provides access to the company’s publicly filed regulatory documents, including current reports on Form 8-K and other submissions made through the U.S. Securities and Exchange Commission’s EDGAR system. As a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease, Inhibikase uses these filings to report material corporate events, financing transactions, governance matters, and key developments in its pulmonary arterial hypertension (PAH) program.
Inhibikase’s recent 8-K filings describe, among other items, the entry into an underwriting agreement for a public offering of common stock and pre-funded warrants, the expected net proceeds from that offering, and amendments to outstanding warrants in connection with plans to advance IKT-001 to a global pivotal Phase 3 study in PAH. Other 8-Ks report financial results for specific periods, updates to corporate presentations, and outcomes of the company’s annual meeting of stockholders, including director elections, auditor ratification, and equity incentive plan amendments.
Through this page, users can review how Inhibikase discloses its clinical development strategy for IKT-001, including the planned two-part adaptive Phase 3 IMPROVE-PAH study, as well as its capital-raising activities that support ongoing research and development. Stock Titan enhances these filings with AI-powered summaries that explain the core points of lengthy documents such as current reports, shelf registration statements, and related exhibits. Investors can also monitor information related to equity offerings, warrant terms, and other securities matters that may affect the company’s capital structure.
By consolidating Inhibikase’s SEC filings and applying AI-driven analysis, this page helps readers quickly understand the regulatory and financial context surrounding the company’s PAH-focused clinical programs and broader corporate activities.
Inhibikase Therapeutics director Vincent Aurentz forfeited 255,299 shares of common stock back to the company. These shares had been received as part of the CorHepta Pharmaceuticals acquisition and were subject to forfeiture if a milestone was not met by the first anniversary of the February 21, 2025 closing date.
On February 21, 2026, the milestone was determined not to have been achieved, triggering the return of all 255,299 shares to the issuer at no cost. After this issuer disposition, Aurentz directly holds 510,596 shares of Inhibikase Therapeutics common stock.
Inhibikase Therapeutics executive Cabell Christopher reported the forfeiture of 338,282 shares of common stock back to the company. These shares had been received as part of the CorHepta Pharmaceuticals acquisition completed on
On
Inhibikase Therapeutics director Amit Munshi reported a forfeiture of previously issued shares. On February 21, 2026, 19,089 shares of common stock were returned to the company after a milestone related to the February 21, 2025 CorHepta Pharmaceuticals acquisition was not achieved. Munshi received no cash or other consideration for this disposition to the issuer.
Following the forfeiture, he holds 38,176 shares of common stock directly and 365,000 shares indirectly through the Amit Munshi Revocable Trust.
Inhibikase Therapeutics, Inc. attracted a significant institutional holder, with ADAR1-affiliated entities reporting beneficial ownership of 9.9% of its common stock. ADAR1 Capital Management, ADAR1 Capital Management GP and manager Daniel Schneeberger report shared voting and dispositive power over between 12.5 million and 12.7 million shares, including milestone warrant shares.
The holdings span limited partnerships, a Spearhead Insurance vehicle and separately managed accounts, with additional milestone warrants contractually limited by a 9.99% beneficial ownership cap. Ownership percentages are based on 120,899,650 Inhibikase common shares outstanding as of November 24, 2025.
Inhibikase Therapeutics, Inc. received an amended Schedule 13G/A showing that Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., and principals Peter Harwin and Tomas Kiselak collectively report beneficial ownership of 12,461,101 shares of Common Stock, representing 9.9% of the class.
The position consists of 8,625,000 shares held by Fund II and the current right to acquire 3,836,101 additional shares through pre-funded warrants, limited by a 9.99% “Beneficial Ownership Limitation.” The 9.9% stake is calculated against 124,461,101 shares of Common Stock outstanding as of the filing date.
Perceptive Advisors LLC and its affiliates report beneficial ownership of 12,816,643 shares of Inhibikase Therapeutics common stock, representing 9.99% of the class. This total includes shares underlying pre-funded and common warrants held by Perceptive Life Sciences Master Fund, Ltd., subject to a 9.99% ownership cap on warrant exercise.
The ownership percentage is based on 120,899,650 shares outstanding as of a recent prospectus supplement, and reflects shared voting and dispositive power among Perceptive Advisors, Joseph Edelman, and the Master Fund. The group certifies the holdings are not for the purpose of changing or influencing control of Inhibikase.
Nantahala Capital Management, LLC and principals Wilmot B. Harkey and Daniel Mack report their beneficial ownership of Inhibikase Therapeutics common stock on an amended Schedule 13G. As of December 31, 2025, they may be deemed to beneficially own 7,037,916 shares, or 5.68% of the outstanding common stock.
This total includes 3,108,624 shares that could be acquired within sixty days through warrant exercises. The reporting persons state they share voting and dispositive power over these shares and certify the holdings are in the ordinary course of business, not for the purpose of changing or influencing control.
Sands Capital Life Sciences Pulse Fund II, L.P. and related entities report a 10.8% beneficial stake in Inhibikase Therapeutics, Inc. They collectively hold 13,018,965 shares of common stock, based on 120,899,650 shares outstanding as of November 20, 2025, as referenced in the issuer's prospectus supplement.
The filing explains that this ownership is attributed to Sands Capital Life Sciences Pulse Fund II, its investment manager Sands Capital Alternatives, LLC, and Frank M. Sands, who has ultimate voting and investment power. It also describes additional Series A-1 and Series B-1 warrants held by the fund that are not counted as beneficially owned because they are not exercisable within 60 days and are subject to a 19.99% ownership cap after exercise.
Inhibikase Therapeutics, Inc. reported a new stock option grant to its Chief Executive Officer and director, Mark T. Iwicki. On January 5, 2026, he was awarded a stock option covering 4,982,706 shares of common stock at an exercise price of $2.01 per share.
The option is described as a right to buy common stock and had no purchase price at grant. It becomes exercisable in 36 equal monthly installments starting on January 5, 2026, and each vesting installment depends on his continued employment through that vesting date. The option relates to 4,982,706 underlying common shares and is scheduled to expire on January 5, 2036, if not exercised earlier.
Inhibikase Therapeutics reported that President & Head of R&D Cabell Christopher received a grant of stock options on January 5, 2026. The award covers 900,117 stock options, each with an exercise price of $2.01 per share, giving the right to buy common stock. According to the disclosure, the options vest in 36 equal monthly installments starting January 5, 2026, and vesting is conditioned on Christopher’s continued employment through each vesting date. Following this grant, Christopher beneficially holds 900,117 derivative securities directly.